Keywords:
Oncology, Haematologic, Musculoskeletal bone, MR, PET-CT, CT, Staging, Segmentation, Comparative studies, Haematologic diseases, Neoplasia, Cancer
Authors:
A. Amlani, O. A. Westerland, M. M. Siddique, M. Streetly, I. El-Najjar, G. Cook, V. Goh; London/UK
DOI:
10.26044/ecr2019/C-2907
Methods and materials
A retrospective study was performed following IRB approval. 25 newly diagnosed myeloma patients (12 male; mean±SD = 61±10 years) underwent simultaneous 18F-FDG PET/CT and WB-MRI prior to treatment.
Inclusion criteria were clinical or biochemical suspicion of multiple myeloma,
no contraindication to either contrast enhanced WB-MRI or 18F-FDG PET/CT,
no previous chemotherapy or radiotherapy,
and a maximum 2 month interval between WB-MRI and PET/CT with no interval treatment.
PET/CT acquisition: Following a 6hr fast,
400 MBq 18F-FDG was administered intravenously.
At 60 +/-5 mins post injection,
imaging was acquired from vertex to feet (GE Discovery PET/CT).
WB-MRI acquisition: Included T2-HASTE,
T1-DIXON,
DWI (B=50 and 900s/mm2) and post-contrast T1-DIXON sequences from vertex to knees (1.5T Magnetom Aera,
Siemens HealthCare,
Erlangen,
Germany).
For quantitative analysis,
regions of interest were drawn at the right iliac crest for each scan: SUV parameters were assessed clinically.
ADC and fat fraction (FF) histogram parameters were calculated using in-house radiomics software.
Associations were assessed using Pearson correlation with corrections for multiple comparisons.